December 18, 2017
Bloomberg BNA Daily Environment Report Includes Comments by Lynn L. Bergeson Regarding FDA Draft Guidance for Nanomaterial Drugs
On December 18, 2017, Lynn L. Bergeson, President of The Acta Group (Acta®), was quoted by the Bloomberg BNA Daily Environment Report in the article “FDA Pushes Risk-Based Approach to Nanomaterial Drugs.” Developers of drugs containing nanomaterials—substances so small they can’t be seen with a regular microscope—got some advice on how to assess their risks in FDA draft guidance issued Dec. 15. […] Without having read it in detail yet, Lynn Bergeson, managing...